Navigation Links
Omeros Announces Discovery in MASP-2 Program
Date:7/31/2012

in the inflammatory response and becomes activated as a result of tissue damage or microbial infection. MASP-2 appears to be unique to, and required for the function of, one of the principal complement activation pathways, known as the lectin pathway. Importantly, inhibition of MASP-2 does not appear to interfere with the antibody-dependent classical complement activation pathway, which is a critical component of the acquired immune response to infection, and its abnormal function is associated with a wide range of autoimmune disorders. MASP-2 is generated by the liver and is then released into the circulation. Adult humans who are genetically deficient in one of the proteins that activate MASP-2 do not appear to be detrimentally affected by the deficiency. Therefore, Omeros believes that it may be possible to deliver MASP-2 antibodies systemically.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, bleeding and central nervous system disorders.

Forward-Looking Statements

This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those section
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros to Present at Deutsche Bank Securities Health Care Conference
2. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
3. Omeros to Present at Jefferies 2012 Global Healthcare Conference
4. Omeros Announces Proposed Public Offering of Common Stock
5. Omeros Prices $30 Million Public Offering of Common Stock
6. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
7. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
8. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
9. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
10. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
11. Misonix Announces New Distribution Agreement For Panama
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)...  Ascendant Solutions, Inc. (Pink Sheets: ASDS ) ... subsidiary, Dougherty,s Holdings, has acquired Springtown Drug (" ... Springtown, Texas , just north of ... pharmacy has provided retail prescriptions, healthcare products and gifts ... . The Springtown ...
(Date:8/31/2015)... Pa. , Aug. 31, 2015 The ... reversed statewide since Pennsylvania State ... life-saving drug kits, naloxone. Heroin and opioid ... Pennsylvania , killing more individuals than ... approximately 2,400 Pennsylvanians died from a drug overdose. ...
(Date:8/31/2015)... , Aug. 31, 2015 Regen BioPharma, ... development of a novel means of delivering its ... RGBP-248, to liver tumors utilizing a clinically approved ... overcomes previous hurdles with gene silencing therapeutics in ... delivered throughout the whole body.  By utilizing a ...
Breaking Medicine Technology:Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 2Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 3Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3
... June 9 Halozyme Therapeutics,Inc. (Nasdaq: ... products targeting the extracellular matrix, today,announced new ... mellitus program at,the American Diabetes Association,s 68th ... company,s proprietary recombinant human,hyaluronidase enzyme (rHuPH20) with ...
... Pivotal Study Highlighted at Recent Arizona Alzheimer,s ... Consortium Annual Conference in Phoenix -, PHOENIX and ... Health Research Institute today announced that they are,actively enrolling patients ... treatment of Alzheimer,s disease. The study will,evaluate the safety and ...
Cached Medicine Technology:Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 2Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 3Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 4Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 5Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease 2Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease 3
(Date:8/31/2015)... ... September 01, 2015 , ... AthleticTraining.com, provider of CEUs ... hours of new premium on-demand video Evidence Based Practice courses ... before 2014 must complete 50 CEUs before December 31, 2015, which must include ...
(Date:8/31/2015)... ... August 31, 2015 , ... Jvion, the ... latest predictive use case focused on helping hospital perform under the Center for ... hospital payments are adjusted based on performance across four domains related to care ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... a wealth of information for specific translation services within the medical and pharmaceutical ... incredible track record of successful work. , ITC Global Translations specializes in professional ...
(Date:8/31/2015)... ... ... When it comes to undergoing a hair transplant, most patients have donor hair moved from ... to the hair on top of the scalp, as well as filling in areas missing ... hair on other areas of their head. , What about patients who have a limited, ...
(Date:8/31/2015)... ... 31, 2015 , ... Wound Care Advantage, a leader in ... to Hyperbaric Medicine Course. The next UHMS approved 40-hour Introduction to Hyperbaric Medicine ... Long Beach, CA. The meeting is open for registration from physicians, clinicians and ...
Breaking Medicine News(10 mins):Health News:Evidence Based Practice Courses: CEUs For Athletic Trainers Just Released 2Health News:Jvion Releases Value-Based Purchasing Predictive Use Case 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 3Health News:Body Hair Transplants to Help Achieve a Full Head of Hair 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 4
... Nearly 2.5 million ... Because nearly 90% of eye injuries are preventable with proper protective eyewear, Defog It antifog ... ... Nearly 2.5 million eye injuries occur each year in the United States, with almost half occurring ...
... YORK, N.Y. (May 18, 2010) Autism Speaks, the ... major sponsor and scientific participant in the 2010 International ... Society of Autism Research, IMFAR brings together 1800 participants ... who will share their latest research into autism,s causes, ...
... Post-surgical improvements on hearing tests greater in those under 65, ... implants provide plenty of benefits for older people with hearing ... well, new research has found. , Dr. David R. ... Milwaukee, examined the medical records of 28 patients aged 65 ...
... marketed as Revatio, study finds , TUESDAY, May 18 ... that causes progressive scarring of the lung tissue might ... Viagra, a new study finds. , The disease, called ... thick and stiff, reducing the ability to breathe. There,s ...
... generation moves into the ranks of the elderly in the ... to develop will be staggering. Without a current cure, and ... a pressing need for novel solutions to address the multifaceted ... IS FAILING MILLIONSAND HOW WE CAN DO BETTER (Prometheus Books, ...
... ... prevalent than ever before. Get the facts on cancer and ways to prevent it from ... ... to educate the nation in the prevention and treatment of cancer. Truecancerfacts.com was written by ...
Cached Medicine News:Health News:Eye Protection at Home Could Help Prevent 1 Million Home Eye Injures: Tips from Defog It Antifog During National Healthy Vision Month 2010 2Health News:Eye Protection at Home Could Help Prevent 1 Million Home Eye Injures: Tips from Defog It Antifog During National Healthy Vision Month 2010 3Health News:Autism Speaks to play key roles at the 2010 International Meeting for Autism Research 2Health News:Autism Speaks to play key roles at the 2010 International Meeting for Autism Research 3Health News:Younger Is Better When Getting Cochlear Implants 2Health News:Viagra May Aid Those With Lung Fibrosis 2Health News:Viagra May Aid Those With Lung Fibrosis 3Health News:The Alzheimer's solution 2Health News:What Doctors Won't Tell Their Patients About Cancer 2
... KeraCel Ophthalmic Products are ... formulation of lint-free MEROCEL polyvinyl ... configured to be beneficial to ... being absorbent, and yet firm ...
... Products provide the surgeon ... products for unparalleled fluid ... of fine microsurgical instruments. ... is highly absorbent, fast ...
... Merocel Ophthalmic Products provide ... fiber free products for ... safe cleaning of fine ... Merocel material is highly ...
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: